Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

April 23, 2020

Study Completion Date

April 23, 2020

Conditions
Pneumonia, ViralCorona Virus InfectionRespiratory FailureEmbolism and Thrombosis
Interventions
DRUG

Tirofiban Injection

Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.

DRUG

Clopidogrel

Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days

DRUG

Acetylsalicylic acid

Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.

DRUG

Fondaparinux

Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay

Trial Locations (1)

20157

L. Sacco Hospital, Milan

All Listed Sponsors
collaborator

"Fondazione Un Cuore per Milano - a no profit foundation"

UNKNOWN

lead

University of Milan

OTHER

NCT04368377 - Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 | Biotech Hunter | Biotech Hunter